SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

Citing “ongoing funding changes,” the U of Iowa will end the Iowa Youth Writing Project and the Iowa Summer Writing Festival at the end of 2025 ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

Sam Altman says ChatGPT-5 feels like a real expert. Launched today, the model can code from scratch and deliver on-demand software generation.